CABA Cabaletta Bio, Inc. Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
Time
Author
Thesis
Company / ticker
Signal
Since call
Position
Source
12:52
Nov 05
Nov 05
r/biotech_stocks
Mixed but constructive CABA update; watch Nov data and 2028 BLA
The author's own investment view is mixed but constructive: the longer cash runway into Q1 2028 and initiation of the second registrational study strengthen CABA's position, while the FDA Type B interaction is also constructive. The postponement of the anticipated BLA submission into 2028 is a negative, particularly because management attributed slower enrollment partly to safety concerns elsewhere in CAR-T. The key near-term catalyst is the November 8–9 ACR presentations on rese-cel efficacy, durability and safety; the main stated risk is the delayed regulatory path and possible future financing before commercialization.
CABA
Cabaletta Bio, Inc.
Long
1ST
Position: Holding
—
About CABA Investor Commentary
Across the available history and selected sources, Buzzberg tracks CABA (Cabaletta Bio, Inc.) across 1 sources: 1 bullish vs 0 bearish calls from 1 authors. Historical directional balance: 100% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 1 total trade idea tracked. Past 7 days, before deduplication: 1 bullish. Latest voices: u/20x_orbust.